After Dasatinib Apotex Debuts US Tasigna Competition
Novartis’ Tyrosine Kinase Inhibitor Nilotinib Launched In US In 2007
Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.
